Human Gene CCND1 (uc001opa.3)
  Description: Homo sapiens cyclin D1 (CCND1), mRNA.
RefSeq Summary (NM_053056): The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb. Mutations, amplification and overexpression of this gene, which alters cell cycle progression, are observed frequently in a variety of human cancers. [provided by RefSeq, Dec 2019].
Transcript (Including UTRs)
   Position: hg19 chr11:69,455,873-69,469,242 Size: 13,370 Total Exon Count: 5 Strand: +
Coding Region
   Position: hg19 chr11:69,456,082-69,466,050 Size: 9,969 Coding Exon Count: 5 

Page IndexSequence and LinksUniProtKB CommentsPrimersGenetic AssociationsMalaCards
CTDGene AllelesRNA-Seq ExpressionMicroarray ExpressionRNA StructureProtein Structure
Other SpeciesGO AnnotationsmRNA DescriptionsPathwaysOther NamesModel Information
Methods
Data last updated at UCSC: 2013-06-14

-  Sequence and Links to Tools and Databases
 
Genomic Sequence (chr11:69,455,873-69,469,242)mRNA (may differ from genome)Protein (295 aa)
Gene SorterGenome BrowserOther Species FASTAVisiGeneGene interactionsTable Schema
AlphaFoldBioGPSEnsemblEntrez GeneExonPrimerGeneCards
GeneNetworkH-INVHGNCHPRDLynxMalacards
MGIneXtProtOMIMPubMedReactomeTreefam
UniProtKBWikipediaBioGrid CRISPR DB

-  Comments and Description Text from UniProtKB
  ID: CCND1_HUMAN
DESCRIPTION: RecName: Full=G1/S-specific cyclin-D1; AltName: Full=B-cell lymphoma 1 protein; Short=BCL-1; AltName: Full=BCL-1 oncogene; AltName: Full=PRAD1 oncogene;
FUNCTION: Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.
SUBUNIT: Interacts with FBXO4 (By similarity). Interacts with either CDK4 or CDK6 protein kinase to form a serine/threonine kinase holoenzyme complex. The cyclin subunit imparts substrate specificity to the complex. Component of the ternary complex CCND1/CDK4/CDKN1B required for nuclear translocation and modulation of CDK4-mediated kinase activity. Interacts directly with CDKN1B. Interacts with UHRF2; the interaction ubiquitinates CCND1 and appears to occur independently of phosphorylation. Can form similar complexes with either CDKN1A or CDKN2A. Interacts with USP2.
INTERACTION: P38398:BRCA1; NbExp=3; IntAct=EBI-375001, EBI-349905; P11802:CDK4; NbExp=10; IntAct=EBI-375001, EBI-295644; Q00534:CDK6; NbExp=2; IntAct=EBI-375001, EBI-295663; P38936:CDKN1A; NbExp=5; IntAct=EBI-375001, EBI-375077; P46527:CDKN1B; NbExp=2; IntAct=EBI-375001, EBI-519280; Q62796:Ralbp1 (xeno); NbExp=2; IntAct=EBI-375001, EBI-3956409; Q96PU4:UHRF2; NbExp=4; IntAct=EBI-375001, EBI-625304;
SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Membrane. Note=Cyclin D- CDK4 complexes accumulate at the nuclear membrane and are then translocated to the nucleus through interaction with KIP/CIP family members (By similarity).
PTM: Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
PTM: Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB. Following DNA damage it is ubiquitinated by some SCF (SKP1- cullin-F-box) protein ligase complex containing FBXO31. SCF-type ubiquitination is dependent on Thr-286 phosphorylation (By similarity). Ubiquitinated also by UHRF2 apparently in a phosphorylation-independent manner. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to its stabilization.
DISEASE: Note=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
DISEASE: Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
DISEASE: Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
SIMILARITY: Belongs to the cyclin family. Cyclin D subfamily.
SIMILARITY: Contains 1 cyclin N-terminal domain.
WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and Haematology; URL="http://atlasgeneticsoncology.org/Genes/BCL1.html";
WEB RESOURCE: Name=NIEHS-SNPs; URL="http://egp.gs.washington.edu/data/ccnd1/";
WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and polymorphism database; URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=CCND1";

-  Primer design for this transcript
 

Primer3Plus can design qPCR Primers that straddle exon-exon-junctions, which amplify only cDNA, not genomic DNA.
Click here to load the transcript sequence and exon structure into Primer3Plus

Exonprimer can design one pair of Sanger sequencing primers around every exon, located in non-genic sequence.
Click here to open Exonprimer with this transcript

To design primers for a non-coding sequence, zoom to a region of interest and select from the drop-down menu: View > In External Tools > Primer3


-  Genetic Association Studies of Complex Diseases and Disorders
  Genetic Association Database (archive): CCND1
CDC HuGE Published Literature: CCND1
Positive Disease Associations: advanced colorectal cancer , benzene toxicity , bladder cancer , bladder cancer, urinary , breast cancer , cervical cancer , colorectal cancer , colorectal cancer, nonpolyposis , endometrial cancer , ER negative , esophageal cancer , esophageal cancer; cardiac cancer , esophageal cancer; gastric cardiac cancer , gastroesophageal cancer , kidney cancer , laryngeal squamous cell carcinoma , liver cancer , lung cancer smoking behavior , Neoplasms , oral cancer , pituitary cancer , prostate cancer , prostatic hyperplasia; prostate cancer , squamous cell carcinoma , squamous cell carcinoma of the head and neck , stomach cancer , Stomach Neoplasms , tumour grade , urinary bladder cancer
Related Studies:
  1. advanced colorectal cancer
    Le Marchand L 2003, Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer., JAMA. 2003 Dec;290(21):2843-8. [PubMed 14657069]
    The CCND1 870A allele may be associated with colorectal cancer, and particularly with forms of the disease that result in severe morbidity and mortality.
  2. benzene toxicity
    Xu, J. N. et al. 2007, Analysis for the association between genetic polymorphisms of XRCC1, XPD, XRCC3, CCND1 and the latency of the occupational chronic benzene poisoning, Zhonghua Yu Fang Yi Xue Za Zhi 2007 41(2) 114-7. [PubMed 17605237]
    The polymorphisms of XRCC1 and CCND1 potentially modify the latency of the chronic benzene poisoning among workers exposed to benzene.
  3. bladder cancer
    Ito, M. et al. 2004, Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer., Urology. 2004 Jul;64(1):74-8. [PubMed 15245939]
    Although CCND1 polymorphism is not able to serve as a prognostic marker for bladder cancer, the CCND1 variant A allele may recessively increase the risk of carcinoma in situ incidence in patients with superficial bladder cancer.
           more ... click here to view the complete list

-  MalaCards Disease Associations
  MalaCards Gene Search: CCND1
Diseases sorted by gene-association score: chronic lymphocytic leukemia* (499), multiple myeloma* (438), von hippel-lindau syndrome* (389), mantle cell lymphoma* (290), colorectal cancer* (132), hairy cell leukemia (43), lymphoma (27), plasma cell leukemia (26), parathyroid adenoma (24), squamous cell carcinoma (20), parathyroid carcinoma (19), retinoblastoma (17), breast cancer (17), salivary gland adenoid cystic carcinoma (17), esophageal cancer (15), b-cell lymphomas (14), prolymphocytic leukemia (14), extramedullary plasmacytoma (13), bowenoid papulosis (13), adenoma (13), follicular lymphoma (12), pancreatic cancer (12), lung cancer (12), hepatocellular carcinoma (11), lymphoma, small cleaved-cell, diffuse (11), breast ductal carcinoma (11), lymphoma, non-hodgkin (11), bile duct carcinoma (11), oral squamous cell carcinoma (11), endometrial cancer (10), oral cancer (10), atypical teratoid rhabdoid tumor (10), malignant iris melanoma (10), estrogen-receptor positive breast cancer (10), familial adenomatous polyposis (10), glioma (9), squamous cell carcinoma, head and neck (9), hemimegalencephaly (9), astrocytoma (9), larynx cancer (9), star syndrome (9), retinal cancer (8), sensory system cancer (8), lymphoma, malt, somatic (8), bladder urothelial carcinoma (8), squamous cell carcinoma of the oral tongue (8), verrucous carcinoma (8), breast papillomatosis (8), hyperparathyroidism-jaw tumor syndrome (7), ductal carcinoma in situ (7), thyroid cancer (7), barrett esophagus/esophageal adenocarcinoma (7), stomach cancer (7), polymorphous low-grade adenocarcinoma (7), adenocarcinoma (7), hidradenocarcinoma (6), gallbladder cancer (6), tongue cancer (6), cll/sll (6), small intestine cancer (6), plasmacytoma (6), chondromyxoid fibroma (6), ocular cancer (6), endometrial stromal sarcoma (6), inflammatory myofibroblastic tumor (6), ethmoid sinus cancer (5), ethmoid sinus adenocarcinoma (5), jejunal adenocarcinoma (5), skin carcinoma in situ (5), superficial urinary bladder cancer (5), prostate lymphoma (5), non-proliferative fibrocystic change of the breast (5), adenomatous polyposis coli (5), nervous system cancer (5), gastrointestinal system benign neoplasm (5), pharynx cancer (5), marginal zone b-cell lymphoma (5), synchronous bilateral breast carcinoma (5), prostate cancer (5), endometrial squamous cell carcinoma (5), balanitis xerotica obliterans (5), mutagen sensitivity (5), gastrointestinal system cancer (5), glioblastoma multiforme (5), keratocystic odontogenic tumor (4), ischemic fasciitis (4), intestinal benign neoplasm (4), pre-malignant neoplasm (4), clear cell renal cell carcinoma (4), lymph node cancer (4), melanoma (3), ovarian cancer, somatic (3), urinary bladder cancer (3), diffuse large b-cell lymphoma (3), pancreatic ductal adenocarcinoma (2), intrahepatic cholangiocarcinoma (2), lung cancer susceptibility 3 (2), papilloma (2), lynch syndrome (2), bladder cancer, somatic (2), adamantinoma of long bones (2), ewing sarcoma (2), cell type cancer (1), reproductive organ cancer (1), female reproductive organ cancer (1), cell type benign neoplasm (1), male reproductive organ cancer (1), gastric cancer, somatic (1)
* = Manually curated disease association

-  Comparative Toxicogenomics Database (CTD)
  The following chemicals interact with this gene           more ... click here to view the complete list

+  Common Gene Haplotype Alleles
  Press "+" in the title bar above to open this section.

-  RNA-Seq Expression Data from GTEx (53 Tissues, 570 Donors)
  Highest median expression: 66.79 RPKM in Cells - Cultured fibroblasts
Total median expression: 523.67 RPKM



View in GTEx track of Genome Browser    View at GTEx portal     View GTEx Body Map

+  Microarray Expression Data
  Press "+" in the title bar above to open this section.

-  mRNA Secondary Structure of 3' and 5' UTRs
 
RegionFold EnergyBasesEnergy/Base
Display As
5' UTR -83.10209-0.398 Picture PostScript Text
3' UTR -1051.793192-0.330 Picture PostScript Text

The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.

-  Protein Domain and Structure Information
  InterPro Domains: Graphical view of domain structure
IPR013763 - Cyclin-like
IPR014400 - Cyclin_A/B/D/E
IPR004367 - Cyclin_C
IPR006671 - Cyclin_N

Pfam Domains:
PF00134 - Cyclin, N-terminal domain
PF02984 - Cyclin, C-terminal domain

SCOP Domains:
47954 - Cyclin-like

Protein Data Bank (PDB) 3-D Structure
MuPIT help
2W96 - X-ray MuPIT 2W99 - X-ray MuPIT 2W9F - X-ray MuPIT 2W9Z - X-ray MuPIT


ModBase Predicted Comparative 3D Structure on P24385
FrontTopSide
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.

-  Orthologous Genes in Other Species
  Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
MouseRatZebrafishD. melanogasterC. elegansS. cerevisiae
No orthologGenome BrowserGenome BrowserNo orthologNo orthologNo ortholog
Gene DetailsGene Details    
Gene SorterGene Sorter    
 RGDEnsembl   
 Protein SequenceProtein Sequence   
 AlignmentAlignment   

-  Gene Ontology (GO) Annotations with Structured Vocabulary
  Molecular Function:
GO:0003714 transcription corepressor activity
GO:0004672 protein kinase activity
GO:0004693 cyclin-dependent protein serine/threonine kinase activity
GO:0005515 protein binding
GO:0008134 transcription factor binding
GO:0016301 kinase activity
GO:0016538 cyclin-dependent protein serine/threonine kinase regulator activity
GO:0019899 enzyme binding
GO:0019901 protein kinase binding
GO:0042826 histone deacetylase binding
GO:0044877 macromolecular complex binding
GO:0070064 proline-rich region binding

Biological Process:
GO:0000082 G1/S transition of mitotic cell cycle
GO:0000122 negative regulation of transcription from RNA polymerase II promoter
GO:0000320 re-entry into mitotic cell cycle
GO:0001889 liver development
GO:0001934 positive regulation of protein phosphorylation
GO:0006351 transcription, DNA-templated
GO:0006355 regulation of transcription, DNA-templated
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006468 protein phosphorylation
GO:0006974 cellular response to DNA damage stimulus
GO:0007049 cell cycle
GO:0007595 lactation
GO:0008284 positive regulation of cell proliferation
GO:0010033 response to organic substance
GO:0010039 response to iron ion
GO:0010165 response to X-ray
GO:0010243 response to organonitrogen compound
GO:0010971 positive regulation of G2/M transition of mitotic cell cycle
GO:0014070 response to organic cyclic compound
GO:0016055 Wnt signaling pathway
GO:0019221 cytokine-mediated signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030857 negative regulation of epithelial cell differentiation
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0031100 animal organ regeneration
GO:0031571 mitotic G1 DNA damage checkpoint
GO:0032026 response to magnesium ion
GO:0032355 response to estradiol
GO:0033197 response to vitamin E
GO:0033327 Leydig cell differentiation
GO:0033598 mammary gland epithelial cell proliferation
GO:0033601 positive regulation of mammary gland epithelial cell proliferation
GO:0042493 response to drug
GO:0043627 response to estrogen
GO:0044321 response to leptin
GO:0045444 fat cell differentiation
GO:0045471 response to ethanol
GO:0045737 positive regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0045787 positive regulation of cell cycle
GO:0048545 response to steroid hormone
GO:0051301 cell division
GO:0051384 response to glucocorticoid
GO:0051412 response to corticosterone
GO:0051592 response to calcium ion
GO:0051726 regulation of cell cycle
GO:0060070 canonical Wnt signaling pathway
GO:0060749 mammary gland alveolus development
GO:0070141 response to UV-A
GO:0071157 negative regulation of cell cycle arrest
GO:0071310 cellular response to organic substance
GO:0097421 liver regeneration
GO:2000045 regulation of G1/S transition of mitotic cell cycle

Cellular Component:
GO:0000307 cyclin-dependent protein kinase holoenzyme complex
GO:0005622 intracellular
GO:0005634 nucleus
GO:0005654 nucleoplasm
GO:0005737 cytoplasm
GO:0005829 cytosol
GO:0005923 bicellular tight junction
GO:0016020 membrane
GO:0017053 transcriptional repressor complex


-  Descriptions from all associated GenBank mRNAs
  JA488709 - Sequence 2 from Patent EP2350321.
LP882416 - Sequence 11 from Patent WO2017180581.
X59798 - Human PRAD1 mRNA for cyclin.
M73554 - Human bcl-1 mRNA, complete CDS.
BC023620 - Homo sapiens cyclin D1, mRNA (cDNA clone MGC:23386 IMAGE:4650919), complete cds.
AB075505 - Homo sapiens neuroblastoma cDNA, clone:Nbla00347, full insert sequence.
JD299574 - Sequence 280598 from Patent EP1572962.
LY623323 - KR 1020180134347-A/11: DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER.
MB416866 - JP 2019518426-A/6: DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER.
JD206507 - Sequence 187531 from Patent EP1572962.
JD255445 - Sequence 236469 from Patent EP1572962.
AK313136 - Homo sapiens cDNA, FLJ93625, Homo sapiens cyclin D1 (PRAD1: parathyroid adenomatosis 1) (CCND1),mRNA.
AK299044 - Homo sapiens cDNA FLJ51281 complete cds, highly similar to G1/S-specific cyclin-D1.
Z23022 - H.sapiens of BCL1 mRNA encoding cyclin.
M74092 - Human cyclin mRNA.
BC025302 - Homo sapiens cyclin D1, mRNA (cDNA clone MGC:39267 IMAGE:5457963), complete cds.
M64349 - Human cyclin D (cyclin D1) mRNA, complete cds.
BC000076 - Homo sapiens cyclin D1, mRNA (cDNA clone MGC:2316 IMAGE:3508088), complete cds.
BC001501 - Homo sapiens cyclin D1, mRNA (cDNA clone MGC:2233 IMAGE:3507598), complete cds.
BC014078 - Homo sapiens cyclin D1, mRNA (cDNA clone MGC:20169 IMAGE:4124540), complete cds.
JD077228 - Sequence 58252 from Patent EP1572962.
JD455214 - Sequence 436238 from Patent EP1572962.
JD118113 - Sequence 99137 from Patent EP1572962.
JD104710 - Sequence 85734 from Patent EP1572962.
JD372498 - Sequence 353522 from Patent EP1572962.
AB385148 - Synthetic construct DNA, clone: pF1KB5663, Homo sapiens CCND1 gene for G1/S-specific cyclin-D1, complete cds, without stop codon, in Flexi system.
KJ890761 - Synthetic construct Homo sapiens clone ccsbBroadEn_00155 CCND1 gene, encodes complete protein.
AM393193 - Synthetic construct Homo sapiens clone IMAGE:100001850 for hypothetical protein (CCND1 gene).
AM393430 - Synthetic construct Homo sapiens clone IMAGE:100001931 for hypothetical protein (CCND1 gene).
AM393593 - Synthetic construct Homo sapiens clone IMAGE:100001857 for hypothetical protein (CCND1 gene).
DQ891848 - Synthetic construct clone IMAGE:100004478; FLH180582.01X; RZPDo839D10134D cyclin D1 (CCND1) gene, encodes complete protein.
DQ895038 - Synthetic construct Homo sapiens clone IMAGE:100009498; FLH180578.01L; RZPDo839D10133D cyclin D1 (CCND1) gene, encodes complete protein.
CU692810 - Synthetic construct Homo sapiens gateway clone IMAGE:100021929 5' read CCND1 mRNA.
KJ896486 - Synthetic construct Homo sapiens clone ccsbBroadEn_05880 CCND1 gene, encodes complete protein.
CR542099 - Homo sapiens full open reading frame cDNA clone RZPDo834A1237D for gene CCND1, cyclin D1 (PRAD1: parathyroid adenomatosis 1); complete cds, without stopcodon.
BT019844 - Homo sapiens cyclin D1 (PRAD1: parathyroid adenomatosis 1) mRNA, complete cds.
BT019845 - Homo sapiens cyclin D1 (PRAD1: parathyroid adenomatosis 1) mRNA, complete cds.
CR536538 - Homo sapiens full open reading frame cDNA clone RZPDo834E0520D for gene CCND1, cyclin D1 (PRAD1: parathyroid adenomatosis 1); complete cds, incl. stopcodon.
LQ834722 - Sequence 26 from Patent WO2018134305.
AY830112 - Homo sapiens cyclin D1 (CCND1) mRNA, partial cds.
S71637 - cyclin D1 {3' truncated transcript} [human, breast cancer cell line MDA MB-453, mRNA Partial Mutant, 117 nt].
JD556176 - Sequence 537200 from Patent EP1572962.
JD301486 - Sequence 282510 from Patent EP1572962.
JD167829 - Sequence 148853 from Patent EP1572962.
JD131227 - Sequence 112251 from Patent EP1572962.
JD057695 - Sequence 38719 from Patent EP1572962.
JD098370 - Sequence 79394 from Patent EP1572962.
JD371152 - Sequence 352176 from Patent EP1572962.
JD261602 - Sequence 242626 from Patent EP1572962.
MA264858 - JP 2017508467-A/178: PHARMACEUTICAL COMPOSITIONS COMPRISING RNA AND USE FOR TREATING CANCER.
MS942534 - Sequence 178 from Patent EP3116513.
JD231894 - Sequence 212918 from Patent EP1572962.
JD275312 - Sequence 256336 from Patent EP1572962.
JD235983 - Sequence 217007 from Patent EP1572962.
JD360572 - Sequence 341596 from Patent EP1572962.
JD316127 - Sequence 297151 from Patent EP1572962.
JD387100 - Sequence 368124 from Patent EP1572962.
MA264862 - JP 2017508467-A/182: PHARMACEUTICAL COMPOSITIONS COMPRISING RNA AND USE FOR TREATING CANCER.
MS942538 - Sequence 182 from Patent EP3116513.
JD232915 - Sequence 213939 from Patent EP1572962.
JD391713 - Sequence 372737 from Patent EP1572962.
JD128474 - Sequence 109498 from Patent EP1572962.
MA264864 - JP 2017508467-A/184: PHARMACEUTICAL COMPOSITIONS COMPRISING RNA AND USE FOR TREATING CANCER.
MS942540 - Sequence 184 from Patent EP3116513.
JD132048 - Sequence 113072 from Patent EP1572962.
JD508264 - Sequence 489288 from Patent EP1572962.
JD191189 - Sequence 172213 from Patent EP1572962.
JD406204 - Sequence 387228 from Patent EP1572962.
JD136719 - Sequence 117743 from Patent EP1572962.
JD270790 - Sequence 251814 from Patent EP1572962.
JD190585 - Sequence 171609 from Patent EP1572962.
JD121732 - Sequence 102756 from Patent EP1572962.
JD100650 - Sequence 81674 from Patent EP1572962.
JD045438 - Sequence 26462 from Patent EP1572962.
JD482870 - Sequence 463894 from Patent EP1572962.
JD217646 - Sequence 198670 from Patent EP1572962.
JD195746 - Sequence 176770 from Patent EP1572962.
JD188170 - Sequence 169194 from Patent EP1572962.

-  Biochemical and Signaling Pathways
  KEGG - Kyoto Encyclopedia of Genes and Genomes
hsa04110 - Cell cycle
hsa04115 - p53 signaling pathway
hsa04310 - Wnt signaling pathway
hsa04510 - Focal adhesion
hsa04630 - Jak-STAT signaling pathway
hsa05200 - Pathways in cancer
hsa05210 - Colorectal cancer
hsa05212 - Pancreatic cancer
hsa05213 - Endometrial cancer
hsa05214 - Glioma
hsa05215 - Prostate cancer
hsa05216 - Thyroid cancer
hsa05218 - Melanoma
hsa05219 - Bladder cancer
hsa05220 - Chronic myeloid leukemia
hsa05221 - Acute myeloid leukemia
hsa05222 - Small cell lung cancer
hsa05223 - Non-small cell lung cancer
hsa05416 - Viral myocarditis

BioCarta from NCI Cancer Genome Anatomy Project
h_gsk3Pathway - Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages
h_cellcyclePathway - Cyclins and Cell Cycle Regulation
h_g1Pathway - Cell Cycle: G1/S Check Point
h_wntPathway - WNT Signaling Pathway
h_p53Pathway - p53 Signaling Pathway
h_btg2Pathway - BTG family proteins and cell cycle regulation
h_carm-erPathway - CARM1 and Regulation of the Estrogen Receptor
h_RacCycDPathway - Influence of Ras and Rho proteins on G1 to S Transition

Reactome (by CSHL, EBI, and GO)

Protein P24385 (Reactome details) participates in the following event(s):

R-HSA-75823 Relocalization of nuclearly localized Cyclin D1 to the cytoplasm
R-HSA-75824 Ubiquitination of Cyclin D1
R-HSA-8952058 CCND1 binds RUNX3 and displaces EP300
R-HSA-8941895 Formation of CDK4/6:CCND complexes
R-HSA-75822 Relocalization of nuclearly localized phospho-(T286):cyclin D1:Cdk4 to cytoplasm
R-HSA-75820 Phosphorylation of Cyclin D1 at T286 by glycogen synthase kinase-3 beta
R-HSA-4395227 CCND1:CREBBP binds NOTCH1 promoter
R-HSA-3215426 COPRS binds CCND1:CDK4:PRMT5:pT5-WDR77
R-HSA-3215385 CDK4 in CCND1:CDK4:PRMT5:WDR77 phosphorylates WDR77
R-HSA-8952062 CCND1 recruits HDAC4 to RUNX3
R-HSA-8952069 HDAC4 deacetylates RUNX3
R-HSA-8938867 CCND3,(CCND1,CCND2) binds RUNX1
R-HSA-8941915 Cip/Kip CDK inhibitors bind CDK4/6:CCND complexes
R-HSA-9008412 CDK4 phosphorylates RUNX2
R-HSA-5205799 CCND1:CDK4:PRMT5:pT5-WDR77 methylates arginine-9 of histone H3 (H3R8)
R-HSA-5661117 CCND1:CDK4:PRMT5:pT5-WDR77 methylates methyl-arginine-9 of histone H3
R-HSA-8848414 Activated PTK6 binds CDKN1B
R-HSA-8848436 PTK6 phosphorylates CDKN1B
R-HSA-8942607 Tyrosine kinases phosphorylate Cip/Kip inhibitors bound to CDK4/6:CCND complexes
R-HSA-5205861 COPRS:CCND1:CDK4:PRMT5:pT5-WDR77 methylates arginine-4 of histone H4 (H4R3)
R-HSA-8942836 CDK4/6:CCND complexes are activated by T-loop phosphorylation of CDK4/6
R-HSA-69227 Cyclin D:CDK4/6 phosphorylates RB1 and prevents RB1 binding to E2F1/2/3:DP1/2 complexes
R-HSA-1226094 Cyclin D:Cdk4/6 mediated phosphorylation of p130 (RBL2) and dissociation of phosphorylated p130 (RBL2) from DP1:E2F4/5 complex
R-HSA-1226095 Cyclin D:CDK4/6 mediated phosphorylation of p107 (RBL1) and dissociation of phosphorylated p107 (p-RBL1) from DP1:E2F4 complex
R-HSA-8951430 RUNX3 regulates WNT signaling
R-HSA-9018519 Estrogen-dependent gene expression
R-HSA-69229 Ubiquitin-dependent degradation of Cyclin D1
R-HSA-8951936 RUNX3 regulates p14-ARF
R-HSA-69231 Cyclin D associated events in G1
R-HSA-8878159 Transcriptional regulation by RUNX3
R-HSA-8939211 ESR-mediated signaling
R-HSA-75815 Ubiquitin-dependent degradation of Cyclin D
R-HSA-1912408 Pre-NOTCH Transcription and Translation
R-HSA-3214858 RMTs methylate histone arginines
R-HSA-6785807 Interleukin-4 and 13 signaling
R-HSA-8934593 Regulation of RUNX1 Expression and Activity
R-HSA-69236 G1 Phase
R-HSA-212436 Generic Transcription Pathway
R-HSA-9006931 Signaling by Nuclear Receptors
R-HSA-69242 S Phase
R-HSA-8878166 Transcriptional regulation by RUNX2
R-HSA-1912422 Pre-NOTCH Expression and Processing
R-HSA-3247509 Chromatin modifying enzymes
R-HSA-449147 Signaling by Interleukins
R-HSA-8878171 Transcriptional regulation by RUNX1
R-HSA-187577 SCF(Skp2)-mediated degradation of p27/p21
R-HSA-8849470 PTK6 Regulates Cell Cycle
R-HSA-453279 Mitotic G1-G1/S phases
R-HSA-73857 RNA Polymerase II Transcription
R-HSA-162582 Signal Transduction
R-HSA-69278 Cell Cycle (Mitotic)
R-HSA-157118 Signaling by NOTCH
R-HSA-4839726 Chromatin organization
R-HSA-1280215 Cytokine Signaling in Immune system
R-HSA-69202 Cyclin E associated events during G1/S transition
R-HSA-69656 Cyclin A:Cdk2-associated events at S phase entry
R-HSA-8848021 Signaling by PTK6
R-HSA-74160 Gene expression (Transcription)
R-HSA-1640170 Cell Cycle
R-HSA-168256 Immune System
R-HSA-69206 G1/S Transition
R-HSA-9006927 Signaling by Non-Receptor Tyrosine Kinases

-  Other Names for This Gene
  Alternate Gene Symbols: BCL1, CCND1_HUMAN, NM_053056, NP_444284, P24385, PRAD1, Q6LEF0
UCSC ID: uc001opa.3
RefSeq Accession: NM_053056
Protein: P24385 (aka CCND1_HUMAN)
CCDS: CCDS8191.1

-  Gene Model Information
 
category: coding nonsense-mediated-decay: no RNA accession: NM_053056.2
exon count: 5CDS single in 3' UTR: no RNA size: 4304
ORF size: 888CDS single in intron: no Alignment % ID: 100.00
txCdsPredict score: 1976.00frame shift in genome: no % Coverage: 99.65
has start codon: yes stop codon in genome: no # of Alignments: 1
has end codon: yes retained intron: no # AT/AC introns 0
selenocysteine: no end bleed into intron: 0# strange splices: 0
Click here for a detailed description of the fields of the table above.

-  Methods, Credits, and Use Restrictions
  Click here for details on how this gene model was made and data restrictions if any.